- Home
- TKLF vs MRKR Comparison
TKLF vs MRKR Comparison
Compare TKLF & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- MRKR
- Stock Information
- Founded
- TKLF 2006
- MRKR N/A
- Country
- TKLF Japan
- MRKR United States
- Employees
- TKLF N/A
- MRKR N/A
- Industry
- TKLF Other Specialty Stores
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- MRKR Health Care
- Exchange
- TKLF Nasdaq
- MRKR Nasdaq
- Market Cap
- TKLF 13.3M
- MRKR 13.4M
- IPO Year
- TKLF 2022
- MRKR N/A
- Fundamental
- Price
- TKLF $4.03
- MRKR $1.12
- Analyst Decision
- TKLF
- MRKR Strong Buy
- Analyst Count
- TKLF 0
- MRKR 3
- Target Price
- TKLF N/A
- MRKR $13.17
- AVG Volume (30 Days)
- TKLF 42.3K
- MRKR 39.8K
- Earning Date
- TKLF 12-18-2024
- MRKR 05-27-2025
- Dividend Yield
- TKLF N/A
- MRKR N/A
- EPS Growth
- TKLF N/A
- MRKR N/A
- EPS
- TKLF 1.70
- MRKR N/A
- Revenue
- TKLF $219,520,631.00
- MRKR $6,591,080.00
- Revenue This Year
- TKLF N/A
- MRKR N/A
- Revenue Next Year
- TKLF N/A
- MRKR N/A
- P/E Ratio
- TKLF $2.37
- MRKR N/A
- Revenue Growth
- TKLF 32.02
- MRKR 99.06
- 52 Week Low
- TKLF $2.00
- MRKR $0.95
- 52 Week High
- TKLF $8.53
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- TKLF 76.81
- MRKR 44.63
- Support Level
- TKLF $3.71
- MRKR $1.09
- Resistance Level
- TKLF $3.90
- MRKR $1.30
- Average True Range (ATR)
- TKLF 0.30
- MRKR 0.09
- MACD
- TKLF 0.07
- MRKR -0.00
- Stochastic Oscillator
- TKLF 88.05
- MRKR 14.29
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.